ArticleAnnals of hematology2024

Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study.

Ruiqi Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.